RT Journal Article
SR Electronic
T1 Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20059733
DO 10.1101/2020.04.14.20059733
A1 Dahlke, Christine
A1 Heidepriem, Jasmin
A1 Kobbe, Robin
A1 Santer, René
A1 Koch, Till
A1 Fathi, Anahita
A1 Ly, My L.
A1 Schmiedel, Stefan
A1 Seeberger, Peter H.
A1 ,
A1 Addo, Marylyn M.
A1 Loeffler, Felix F.
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.14.20059733.abstract
AB SARS-CoV-2 is the causative agent of COVID-19 and is a severe threat to global health. Patients infected with SARS-CoV-2 show a wide range of symptoms and disease severity, while limited data is available on its immunogenicity.Here, the kinetics of the development of SARS-CoV-2-specific antibody responses in relation to clinical features and dynamics of specific B-cell populations are reported. Immunophenotyping of B cells was performed by flow cytometry with longitudinally collected PBMCs. In parallel, serum samples were analyzed for the presence of SARS-CoV-2-specific IgA, IgG, and IgM antibodies using whole proteome peptide microarrays. Soon after disease onset in a mild case, we observed an increased frequency of plasmablasts concomitantly with a strong SARS-CoV-2-specific IgA response. In contrast, a case with more severe progression showed a delayed, but eventually very strong and broad SARS-CoV-2-specific IgA response.This case study shows that determining SARS-CoV-2-specific antibody epitopes can be valuable to monitor the specificity and magnitude of the early B-cell response, which could guide the development of vaccine candidates. Follow-up studies are required to evaluate whether the kinetics and strength of the SARS-CoV-2-specific IgA response could be potential prognostic markers of viral control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the German Federal Ministry of Education and Research [BMBF, Grant number 13XP5050A], the MPG-FhG cooperation [Glyco3Display], the Max Planck Society, and the German Center for Infection Research [DZIF TTU01921].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings are available online as supporting information or upon reasonable request from the corresponding authors.